KOD News
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and...
PR Newswire
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and...
PR Newswire
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
Four biotech companies face key fall readouts that could influence the development and commercial prospects of their pipelines.
Zacks
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
Zacks
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus
KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.
Zacks
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results PR Newswire PALO ALTO, Calif., Aug. 13, 2026 PALO ALTO, Calif., Aug. 13, 2026 /PRNewswire/ -- Kodiak Sciences...
PR Newswire
KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema
Kodiak launches a global phase III study of KSI-501 in DME, testing its dual IL-6 and VEGF approach for durable disease control.
Zacks
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema PR Newswire PALO ALTO, Calif., Aug. 10...
PR Newswire
Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026
Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026 Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3...
PR Newswire
Kodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should Know
Key PointsThe chief financial officer of Kodiak Sciences reported selling 30,000 shares for a total transaction value of approximately $1.02 million on June 4, 2026...
Nasdaq News: Markets
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know
KOD surges on positive phase III Zenkuda data, accelerated regulatory plans, advancing late-stage programs and a strengthened balance sheet.
Zacks